BOLT

Bolt Biotherapeutics (BOLT)

About Bolt Biotherapeutics (BOLT)

Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Its pipeline includes BDC-1001, a HER2-targeting Boltbody Immune-Stimulating Antibody Conjugate (ISAC), BDC-3042, a myeloid-modulating antibody, and multiple Boltbody ISAC collaboration programs. The company was founded by Edgar G. Engleman on January 22, 2015 and is headquartered in Redwood City, CA.

Details

Daily high

$0.65

Daily low

$0.62

Price at open

$0.64

52 Week High

$1.56

52 Week Low

$0.54

Market cap

24.1M

Dividend yield

0.00%

Volume

35,031

Avg. volume

138,624

P/E ratio

-.36

Bolt Biotherapeutics News